Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chordoma is a rare type of cancer, which occurs in the spine region or from the base of the skull to the tailbone. Chordoma is included in a group of malignant bone and soft tissue tumors called sarcomas. Chordomas are the most common tumor of the sacrum and cervical spine.

Chordoma tumors can press the spine, brain, and nerves as they grow causing nerve problems such as tingling, numbness, weakness, lack of bladder or bowel control, sexual dysfunction, vision problems, endocrine problems, and swallowing difficulties.

Chordomas are generally treated depending upon its location, size, and appearance. However, even after the initial surgical treatment, chordomas may regrow or spread in other parts of the body. Chordomas are most commonly spread to the bones, lungs, liver or lymph nodes. The treatment options include surgery, radiation therapy, targeted therapy, and chemotherapies in advanced stages. The most frequently used treatment is targeted therapy, where the drugs specifically target cancerous cells.

The global chordoma disease therapeutics market size is expected to be valued at US$ 5,296.31 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

Figure 1. Global Chordoma Disease Therapeutics Market Value (US$ Mn), by Region, 2020

Chordoma Disease Therapeutics  | Coherent Market Insights

Increasing drug approvals for chordoma treatment is expected to propel the market growth over the forecast period

Increasing drug approvals from regulatory authorities for the treatment of chordoma is expected to drive growth of the chordoma disease therapeutics market over the forecast period. For instance, in May 2018, Bavarian Nordic A/S, a pharmaceutical company, received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BN-Brachyury, a novel cancer vaccine indicated for the treatment of chordoma.  

Figure 2. Global Chordoma Disease Therapeutics Market Share (%), by Drug Class, 2020

Chordoma Disease Therapeutics  | Coherent Market Insights

Increasing adoption of strategies such as mergers, agreements, and collaborations by key players is expected to drive the market growth over the forecast period

Market players are focused on adoption of inorganic growth strategies such as collaborations and agreements to strengthen their position in the chordoma disease therapeutics market. For instance, in January 2019, Biothera Pharmaceuticals entered into a licensing agreement with Cipla Limited for its potential bevacizumab biosimilar, BAT1706. Through this agreement, Cipla Limited received the rights to distribute and market the biosimilar in emerging markets.

Chordoma Disease Therapeutics Market Restraint

Chemotherapeutic drugs approved for the treatment of chordoma are not always effective and have several side effects such as nausea, headache, and hair loss, which is expected to restrain the market growth over the forecast period. Also, low prevalence of the disease and limitations associated with the treatment are factors affecting the market growth, followed by the high cost of diagnosis, treatment, and research & development.

request-sample

Chordoma Disease Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: USD 4,963.74 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.7% 2027 Value Projection: USD  8,339.2 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Class: Antimetabolites, Anthracycline, VEGFR inhibitors, EGFR inhibitor, Others.
  • By Treatment Type: Chemotherapy, Targeted Therapy.
  • By End User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd. and Mylan N.V.

Growth Drivers:
  • Increasing research and development activities.
  • Increasing product approvals.
  • Increasing prevalence of bone cancer.
Restraints & Challenges:
  • Limitations associated with treatment.

Global Chordoma Disease Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

Treatment options of cancer such as chemotherapy can weaken the immune system of cancer patients and increases the risk of getting infected. Hence, people suffering from cancer such as chordoma are at higher risk of developing serious complications due to COVID-19 disease. However, considering the criticality of the chordoma disease it has been recommended by the regulatory authorities to not delay of postpone the chemotherapy or immunotherapy for the treatment of chordoma disease.

Healthcare providers are adopting telehealth solutions to conduct their services for cancer patients while maintain the social distancing to combat COVID-19 pandemic without compromising the health of cancer patients. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking following measures to reduce the spread of COVID-19 infection.

  • Hospitals have restricted entries of visitors and only emergency cases are being handled.
  • A screening for possible symptoms of COVID-19 is being performed for all the people who are entering the hospitals.
  • Healthcare givers are encouraging patients to conduct patients’ schedule appointments via telemedicine platforms.

Key Players

Major players operating in the global chordoma disease therapeutics market include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.

Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.

Market Dynamics

The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.    

Key features of the study:

  • This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chordoma disease therapeutics market based on the following parameters – company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market

Detailed Segmentation:

  • Global Chordoma Disease Therapeutics Market, By Drug Class:
    • Antimetabolites
    • Anthracycline
    • VEGFR Inhibitors
    • EGFR Inhibitor
    • Others
  • Global Chordoma Disease Therapeutics Market, By Treatment Type:
    • Chemotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Others
  • Global Chordoma Disease Therapeutics Market, By End User:
    • Hospitals
    • Clinics
    • Oncology Centers
    • Others
  • Global Chordoma Disease Therapeutics Market, By Region:
    • North America
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR Inhibitors
        • EGFR Inhibitor
        • Others
      • By Treatment Type
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Oncology Centers
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bavarian Nordic A/S
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Amgen, Inc.
    • Bristol-Myers Squibb and Company
    • Novartis International AG
    • Bayer AG
    • Reddy’s Laboratories Ltd.
    • Mylan N.V.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Treatment Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Chordoma Disease Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
    • Impact assessment
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Government measures to combat COVID-19
  5. Global Chordoma Disease Therapeutics Market, By Drug Class, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Antimetabolites
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Anthracycline
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • VEGFR Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • EGFR Inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Radiation Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Chordoma Disease Therapeutics Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Oncology Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Chordoma Disease Therapeutics Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • GlaxoSmithKline Plc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bavarian Nordic
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi SA
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca plc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb and Company
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy’s Laboratories Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 26 figures on "Chordoma Disease Therapeutics Market” - Global forecast to 2027

Frequently Asked Questions

The global chordoma disease therapeutics market size was valued at US$ 4,963.74 million in 2019 and is expected to exhibit a CAGR of 6.7% between 2020 and 2027.
Increasing research and development activities, increasing prevalence of bone cancer, and increasing launches of new chordoma disease therapeutics are driving the chordoma disease therapeutics market growth.
VEGFR inhibitor held major market share in 2019 owing to increasing product approvals during the forecast period.
North America chordoma disease therapeutics market is expected to generate highest revenue share during the forecast period
Major key factors hampering the growth of the market include limitations associated with the treatment of chordoma and ineffectiveness of chemotherapeutic drugs.
Major players operating in the global chordoma disease therapeutics market include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, and other prominent players.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner